Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Q3 2023 Earnings Presentation
14 slides from Indivior Pharmaceuticals's earnings presentation, Nov 9, 2023
Slide 1: Q3 2023 Results
Q3 2023 Results November 9, 2023
Slide 2: Important cautionary statement regarding forward-looking statements
Important cautionary statement regarding forward-looking statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, statements regarding: financial guidance for 2023 and medium- and long-term growth outlook; the expected
Slide 3: Mark Crossley, Chief Executive Officer
Mark Crossley Chief Executive Officer
Slide 4: Q3 2023 key messages
Q3 2023 key messages Strong top-line results – total NR1 $271m, +17% YOY / SUBLOCADE®2 NR $167m, +55% YOY FY 2023 SUBLOCADE guidance updated – NR now expected to be $610m to $630m (vs. $590m to $630m) Expansion of commercial capabilities – investments focused on U.S. SUBLOCADE teams Legacy anti-trus
Slide 5: Transactions to secure supply, strengthen OUD pipeline
Transactions to secure supply, strengthen OUD pipeline • Acquired aseptic manufacturing facility in Raleigh, North Carolina • In-house capability supports SUBLOCADE and PERSERIS®1 peak NR delivery • Acquired full ownership of INDV-2000 (oral Orexin-1 receptor antagonist) from C4X Discovery • Potenti
Slide 6: Executing clear strategies for value creation
Executing clear strategies for value creation 1 2 3 4 Grow Build & Optimize SUBLOCADE Diversify Progress Operating >$1.5bn Revenue Pipeline Model • SUBLOCADE Q3 2023 NR of $167m, • PERSERIS® Q3 2023 NR of $11m, • AELIS AEF0117 (CUD3): Phase 2B • $774m of gross cash and investments7 as +55% vs. Q3 20
Slide 7: Ryan Preblick, Chief Financial Officer
Ryan Preblick Chief Financial Officer
Slide 8: Q3 2023 financial highlights
Q3 2023 financial highlights Key Takeaways (vs. Q3 2022) Operating Results – Reported and Adjusted2 Adjusted ➤ Top-line NR growth of 17% (16% at constant FX) $ mil Q3 23 Q3 22 Change Net Revenue: 271 232 17% ✓ U.S. NR up 20% U.S. 227 189 20% ✓ ROW NR up 2% (unchanged at constant FX) ROW3 44 43 2% Q3
Slide 9: Cash & borrowing position
Cash & borrowing position Cash & Borrowing Key Takeaways Total gross cash & investments of $774m1 ➤ Anti-trust MDL settlement payment of $385m for Direct Purchasers to be paid in November 2023; Q3 23 FY 22 Other Anti-trust MDL settlement payments include ($ in mil.) the End-Payors2 of $30m in Q3’23
Slide 10: FY 2023 guidance updated
FY 2023 guidance updated1 • SUBLOCADE NR now expected to be $610m to $630m (vs. $590m to $630m) • SG&A expected to increase modestly primarily for incremental growth investments behind SUBLOCADE FY 2023 Updated Guidance1 ($ in mil.) Additional Top-Line Assumptions ➤ OPVEE NR impact immaterial reflec
Slide 11: Acquisition of manufacturing operation
Acquisition of manufacturing operation • Approximate 80,000 sq. ft. multi-use, sterile manufacturing site • Completed purchase on November 1st ✓ Upfront consideration of $5.5m ✓ Plus estimated assumed contract liabilities of approximately $30m through 2025 • Expecting modest annual adjusted operatin
Slide 12: Appendix
Appendix 12
Slide 13: Financial Reconciliation: Adjusted Results
Financial Reconciliation: Adjusted Results Reconciliation of gross profit to adjusted gross profit Q3 Q3 YTD YTD 2023 2022 2023 2022 For the three and nine months ended September 30 $m $m $m $m Gross profit 225 192 665 544 Exceptional items and other adjustments in cost of sales 3 — 5 — Adjusted gro
Slide 14: Indivior
Nz ANS INDIVIOR
Indivior Pharmaceuticals — Q3 2023 Earnings Presentation on 6ix